The Viral Conjunctivitis drugs in development market research report provides comprehensive information on the therapeutics under development for Viral Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Viral Conjunctivitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued products.
GlobalData tracks nine drugs in development for Viral Conjunctivitis by eight companies/universities/institutes. The top development phase for Viral Conjunctivitis is preclinical with six drugs in that stage. The Viral Conjunctivitis pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Viral Conjunctivitis pipeline products market are: Okogen, IVIEW Therapeutics and Invirsa.
The key targets in the Viral Conjunctivitis pipeline products market include 23S Ribosomal RNA, Cellular Tumor Antigen p53, and DNA Polymerase.
The key mechanisms of action in the Viral Conjunctivitis pipeline product include DNA Polymerase Inhibitor with one drug in Preclinical. The Viral Conjunctivitis pipeline products include two routes of administration with the top ROA being Ophthalmic and two key molecule types in the Viral Conjunctivitis pipeline products market including Small Molecule, and Enzyme.
Viral Conjunctivitis overview
Viral conjunctivitis, or pinkeye, is a common, self-limiting condition that is typically caused by adenovirus. Viral conjunctivitis is highly contagious, usually for 10–12 days from onset as long as the eyes are red. Symptoms include itchy eyes, tearing, redness, discharge, and light sensitivity (with corneal involvement). Treatment includes lubricants, vasoconstrictors, and antihistamines.
For a complete picture of Viral Conjunctivitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
